The trading price of InflaRx N.V. (NASDAQ:IFRX) closed higher on Friday, October 08, closing at $2.69, 13.50% higher than its previous close.
Traders who pay close attention to intraday price movement should know that it fluctuated between $2.39 and $2.69. In examining the 52-week price action we see that the stock hit a 52-week high of $6.88 and a 52-week low of $2.23. Over the past month, the stock has lost -10.03% in value.
InflaRx N.V., whose market valuation is $104.69 million at the time of this writing, is expected to release its quarterly earnings report Oct 27, 2021 – Nov 01, 2021. Investors’ optimism about the company’s current quarter earnings report is understandable. Analysts have predicted the quarterly earnings per share to grow by -$0.36 per share this quarter, however they have predicted annual earnings per share of -$1.32 for 2021 and -$1.44 for 2022. It means analysts are expecting annual earnings per share growth of 14.30% this year and -9.10% next year.
A company’s earnings reviews provide a brief indication of a stock’s direction in the short term, where in the case of InflaRx N.V. No upward and no downward comments were posted in the last 7 days. On the technical side, indicators suggest IFRX has a Hold on average for the short term. According to the data of the stock’s medium term indicators, the stock is currently averaging as a 50% Sell, while an average of long term indicators suggests that the stock is currently 100% Sell.
Here is the average analyst rating on the stock as represented by 1.00 to 5.00, with the extremes of 1.00 and 5.00 suggesting the stock should be considered as either strong buy or strong sell respectively. The number of analysts that have assigned IFRX a recommendation rating is 6. Out of them, 0 rate it a Hold, while 3 recommend Buy, whereas 1 assign an Overweight rating. 0 analyst(s) have tagged InflaRx N.V. (IFRX) as Underweight, while 2 advise Sell. Analysts have rated the stock Hold, likely urging investors to take advantage of the opportunity to add to their holdings of the company’s shares.
A quick review shows that IFRX’s price is currently 1.57% off the SMA20 and 4.25% off the SMA50. The RSI metric on the 14-day chart is currently showing 54.28, and weekly volatility stands at 6.98%. When measured over the past 30 days, the indicator reaches 5.97%. InflaRx N.V. (NASDAQ:IFRX)’s beta value is currently sitting at 0.43, while the Average True Range indicator is currently displaying 0.17. With analysts defining $2.11-$13.65 as the low and high price targets, we arrive at a consensus price target of $7.55 for the trailing 12-month period. The current price is about 21.56% off the estimated low and -407.43% off the forecast high, based on this estimate. Investors will be thrilled if IFRX’s share price rises to $8.44, which is the median consensus price. At that level, IFRX’s share price would be -213.75% below current price.
To see how InflaRx N.V. stock has been performing in comparison to its peers in the industry, here are the numbers: IFRX stock’s performance was 13.50% in the latest trading, and -42.52% in the past year, while Pieris Pharmaceuticals Inc. (PIRS) has traded -1.66% on the day and positioned 119.91% higher than it was a year ago. InflaRx N.V. has a P/E ratio of 0. Also in last trading session, the S&P 500 Index has plunged -0.19%, while the Dow Jones Industrial also saw a negative session, down -0.03% on the day.
An evaluation of the daily trading volume of InflaRx N.V. (NASDAQ:IFRX) indicates that the 3-month average is 246.21K. However, this figure has increased over the past 10 days to an average of 0.61 million.
Currently, records show that 44.19 million of the company’s shares remain outstanding. The insiders hold 14.89% of outstanding shares, whereas institutions hold 25.70%. The stats also highlight that short interest as of Sep 14, 2021, stood at 0.36 million shares, resulting in a short ratio of 0.81 at that time. From this, we can conclude that short interest is 0.82% of the company’s total outstanding shares. It is noteworthy that short shares in September were up slightly from the previous month’s figure, which was 0.13 million. However, since the stock’s price has seen -46.52% year-to-date, investors’ interest is likely to be reignited due to its potential to move even lower.